News & Views

Adobestock 602058904

First patient dosed in Phase 1 Trial

Iksuda announces first patient dosed in Phase 1 trial of IKS014

Adobestock 427889993

Iksuda deepens clinical pipeline

Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 antibody drug conjugate programme from LegoChem Biosciences

Adobestock 550344920

LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up to six targets

Adobestock 427889993

Iksuda Therapeutics closes $47 million financing round

• Funding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need • Investment round led by Korean-based Mirae Asset Capital and Celltrion

Adobestock 550344920

Iksuda enters license agreement with University of Goettingen

Iksuda Therapeutics enters license agreement with University of Goettingen to develop a new generation of antibody drug conjugates

Adobestock 427889993

Licensing agreement with LegoChem Biosciences

LegoChem Biosciences and Iksuda enter Licensing Agreement for Antibody Drug Conjugate program

Adobestock 550344920

LCB and Iksuda Enter into a Multi-Target Research Collaboration

LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

Adobestock 427889993

Forging stable relationships for Antibody-Drug Conjugates

DCs are a class of biopharmaceuticals that target cancer cells while leaving healthy cells alone.

Adobestock 550344920

Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression

IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer

Adobestock 427889993

The ADC Jigsaw

Intro

Adobestock 550344920

Iksuda Therapeutics and Femtogenix sign license agreement

Agreement gives Iksuda access to Femtogenix’s therapeutic payloads to advance lead ADC for difficult-to-treat solid tumours

Adobestock 427889993

Iksuda Therapeutics move into The Biosphere and open a US based office

We’re excited to announce our move into a brand new, purpose built facility, The Biosphere at Newcastle Helix.

Adobestock 550344920

Glythera Announces Corporate Name Change and Rebranding to Iksuda Therapeutics

New identity reflects transition in corporate focus, from technology licensing to drug development, for previously untreatable cancers

Adobestock 427889993

Glythera appoints Professor Kerry Chester to SAB

Appointment supports the development of the Company’s pipeline

Adobestock 550344920

Glythera appoints Chief Scientific Officer and strengthens SAB

Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates

Adobestock 427889993

Positive Outcome of Proof-of-Concept Study with Glythera and Follow on Drug Development Partnership

Successful proof-of-concept study leads to Affimer drug conjugate development partnership

Adobestock 550344920

Glythera licenses novel payload class from Cancer Research UK for the development of next-generation antibody drug conjugates

Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor programme for the development of ADCs conjugated using its highly stable conjugation platform, PermaLink®

Adobestock 427889993

Glythera and IONTAS enter into license agreement for the development of multiple antibodies for next-generation Antibody Drug Conjugates

IONTAS will provide Glythera with antibodies from its fully human antibody libraries

Adobestock 550344920

Glythera appoints Dr Mike Owen as non-executive director

Glythera Limited (‘Glythera’), the next generation antibody drug conjugate (‘ADC’) development company, is pleased to announce the appointment of Dr Mike Owen to the Board as a non-executive director with immediate effect.

Adobestock 427889993

Glythera launches UK government funded project to develop safer and more efficacious ADCs for the treatment of difficult-to-treat tumours

Development of proprietary next generation ADC portfolio

Adobestock 550344920

Glythera demonstrates improved activity and safety of PermaLink®-based ADC

Appoints Scientific Advisory Board

Adobestock 427889993

Glythera wins prestigious biomedical award

2014 Biomedical Awards, hosted by Bionow at the BALTIC Centre

Adobestock 550344920

Avacta and Glythera announce collaboration to develop novel, potentially highly potent, drug class

The collaboration will evaluate the use of Avacta’s Affimer technology in combination with Glythera’s PermaLink conjugation chemistry

Adobestock 427889993

Glythera-led consortium wins Industrial Biotechnology Catalyst funding

£248,000 to develop high-throughput glycosylation assay

Adobestock 550344920

Glythera unveils PermaLink®, its proprietary ADC cysteine linker technology

A next generation linker displaying very high stability with improved selectivity and specificity

Adobestock 427889993

Glythera’s Environmental Policy

We are delighted to announce Glythera’s environmental policy.

Adobestock 550344920

Biomedical start-ups benefit from dose of northern exposure

While City investors and Westminister politicians have been weighing a Pfizer bid for AstraZeneca, a very different attempt to capitalise on UK scientific research has launched in the north of England.

Adobestock 427889993

Glythera STEM Ambassadors

Glythera’s CEO David Simpson and Glythera’s Technical Director Jenny Thirlway are fully approved STEM Ambassadors!

Adobestock 550344920

Newcastle drugs company Glythera Ltd forges new partnership with BioOutsource Ltd

Newcastle-based Glythera Ltd, a biotechnology company specialising in the development of the next generation of biological therapeutics that are used in treatments for diseases like cancer, has joined up with Glasgow firm BioOutsource Ltd. www.thejournal.co.uk

Adobestock 427889993

Glythera shortlisted for 2014 Biomedical Awards

Sixteen companies have been shortlisted within five categories for the 2014 Biomedical Awards Ceremony. The event will celebrate the diversity of the companies within the North of England’s biomedical sector, and the strength and depth of the cluster.

Sign up for more news

Thank you
*required field
*required field
*required field
I confirm that I have read the data protection and Privacy Policy and that I agree to the processing of my personal data